Among the most promising molecules, ITE, an endogenous AhR agonist, reduces the aggressiveness of triple-negative breast cancer (TNBC) by downregulating JAG1-NOTCH1 signaling [66]. The gene discussed is NOTCH1; the disease is triple-negative breast carcinoma.